Top

Reactions Weekly

Published in:

01-09-2021 | Timolol | Case report

Epidermal-growth-factor-receptor-antagonists

Paronychia with pseudopyogenic granulomas: 10 case reports

Published in: Reactions Weekly | Issue 1/2021

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Olamiju B, et al. Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies. Journal of the American Academy of Dermatology 84: 806-808, No. 3, Mar 2021. Available from: URL: http://doi.org/10.1016/j.jaad.2020.06.010CrossRef

Title: Epidermal-growth-factor-receptor-antagonists
Paronychia with pseudopyogenic granulomas: 10 case reports
Publication date: 01-09-2021
Publisher: Springer International Publishing
Keywords: Timolol
Nitrate
Cryotherapy
Cryotherapy
Paronychia
Afatinib
Erlotinib
Osimertinib
Cetuximab
Published in: Reactions Weekly / Issue 1/2021
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-02125-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Epidermal-growth-factor-receptor-antagonists

Paronychia with pseudopyogenic granulomas: 10 case reports

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Aspirin

Voluntary recall of Teligent Pharma's lidocaine topical solution

Immune-globulin/steroids

Cetuximab/cisplatin/docetaxel

Ipilimumab/nivolumab

Multiple drugs